RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
RIGL$42.05+6.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive Loss
(In thousands)
| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Year Ended December 31, | |||||||
| · 2023 · 2022 · 2021 | ||||||||
| Net loss | $(25,091) | | $(58,573) | | $(17,914) | |||
| Other comprehensive gain (loss): | | | | | | | | |
| Net unrealized gain (loss) on short-term investments | 161 | | (51) | | (98) | |||
| Comprehensive loss | $(24,930) | | $(58,624) | | $(18,012) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.